Harvard Bioscience (NASDAQ:HBIO – Get Rating) had its price objective reduced by equities researchers at Benchmark to $3.00 in a note issued to investors on Tuesday, Stock Target Advisor reports. Benchmark’s price objective points to a potential upside of 29.31% from the company’s previous close.
A number of other research firms have also recently issued reports on HBIO. StockNews.com initiated coverage on shares of Harvard Bioscience in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. KeyCorp dropped their price objective on shares of Harvard Bioscience from $7.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, November 9th.
Harvard Bioscience Stock Performance
NASDAQ:HBIO opened at $2.32 on Tuesday. Harvard Bioscience has a 1 year low of $2.10 and a 1 year high of $7.84. The firm has a 50 day moving average of $2.56 and a 200-day moving average of $3.27. The company has a current ratio of 2.43, a quick ratio of 1.20 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $96.65 million, a P/E ratio of -13.65 and a beta of 1.73.
Insider Buying and Selling
Institutional Trading of Harvard Bioscience
Several institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Arbitrage SA raised its position in shares of Harvard Bioscience by 47.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 3,200 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of Harvard Bioscience by 68.4% in the 2nd quarter. Lazard Asset Management LLC now owns 11,989 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 4,869 shares during the period. Amalgamated Bank acquired a new position in shares of Harvard Bioscience in the 1st quarter valued at $38,000. Greenwood Capital Associates LLC grew its holdings in shares of Harvard Bioscience by 3.1% in the 1st quarter. Greenwood Capital Associates LLC now owns 222,979 shares of the medical instruments supplier’s stock valued at $1,385,000 after buying an additional 6,616 shares during the period. Finally, Bank of America Corp DE grew its holdings in shares of Harvard Bioscience by 44.9% in the 1st quarter. Bank of America Corp DE now owns 25,755 shares of the medical instruments supplier’s stock valued at $160,000 after buying an additional 7,976 shares during the period. Institutional investors own 71.44% of the company’s stock.
About Harvard Bioscience
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.
- Get a free copy of the StockNews.com research report on Harvard Bioscience (HBIO)
- International Game Technology is Well Worth the Gamble
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Use The Airbnb Stock Implosion to Your Advantage
- Why Lowe’s Is Up And Home Depot Down
- The TJX Companies Could Break Out To New Highs
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.